Advanced search
Publication Cover
Hematology Volume 21, 2016 - Issue 5
Submit an article Journal homepage
1,656
Views
7
CrossRef citations to date
0
Altmetric
Hematological Malignancy

Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience

Xin ZhouDepartment of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China
,
Jun XiaDepartment of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China
,
Jingjue MaoDepartment of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China
,
Feng ChengDepartment of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China
,
Xifeng QianDepartment of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China
&
Hongfeng GuoDepartment of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, ChinaCorrespondence[email protected]
Pages 280-286 | Published online: 01 Mar 2016

References

  • Kyle RA, Rajkumar SV. Treatment of multiple myeloma. A comprehensive review. Clin Lymphoma Myeloma. 2009;9:278–88. doi: 10.3816/CLM.2009.n.056
  • International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer incidence and Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed 31 March 2015).
  • Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good research practices task force report. Value Health. 2009;12:409–18. doi: 10.1111/j.1524-4733.2008.00489.x
  • Mehta J, Duff SB, Gupta S. Cost effectiveness of bortezomib in the treatment of advanced multiple myeloma. Manag Care Inter Face. 2004;17:52–61.
  • Hornberger J, Rickert J, Dhawan R, Liwing J, Aschan J, Löthgren M. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective. Eur J Haematol. 2010;85:484–91. doi: 10.1111/j.1600-0609.2010.01526.x
  • Möller J, Nicklasson L, Murthy A. Cost-effectiveness of novel relapsed-refractory multiple myeloma therapies in Norway: lenalidomide plus dexamethasone vs bortezomib. J Med Econ. 2011;14:690–7. doi: 10.3111/13696998.2011.611841
  • The Publicity Medicine Prices of Jiangsu. Available from: http://yy.jspn.net (accessed October 2014).
  • National Development and Reform Commission (NDRC). Available from: http://en.ndrc.gov.cn/ (accessed October 2014).
  • Kumar SK, Rajkumar SV, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood. 2008;111:2516–20. doi: 10.1182/blood-2007-10-116129
  • Ludwig H, Beksac M, Blade J, Cavenagh J, Cavo M, Delforge M, et al. Multiple myeloma treatment strategies with novel agents in 2011: a European perspective. Oncologist. 2011;16:388–403. doi: 10.1634/theoncologist.2010-0386
  • van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2011;37:266–83. doi: 10.1016/j.ctrv.2010.08.008
  • National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology Multiple Myeloma (V2.2015). Available from: http://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf (accessed September 2014).
  • Multiple Myeloma Working Party of the Chinese Group. Guidelines for treatment of multiple myeloma. Zhonghua Nei Ke Za Zhi. 2008;47:869–72.
  • Chinese Medical Association, Chinese Society of Hematology, Multiple Myeloma Working Party of the Chinese Group. Guidelines for treatment of multiple myeloma. Zhonghua Nei Ke Za Zhi. 2013;52:791–5.
  • Peng LB, Tan CQ, Wan XM. Cost-utility analysis in China: differences and difficulties compared with developed countries. Pharmacoeconomics. 2007;25:619. doi: 10.2165/00019053-200725070-00007
  • Ghatnekar O, Alvegard T, Conradi N, Lenhoff S, Mellqvist UH, Persson U, et al. Direct hospital resource utilization and costs of treating patients with multiple myeloma in Southwest Sweden: a 5-year retrospective analysis. Clin Ther. 2008;30:1704–13. doi: 10.1016/j.clinthera.2008.09.003
  • Armoiry X, Fagnani F, Benboubker L, Facon T, Fermand JP, Hulin C, et al. Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs: a multi-centre retrospective cohort study. J Clin Pharm Ther. 2011;36:19–26. doi: 10.1111/j.1365-2710.2009.01153.x
  • Koleva D, Cortelazzo S, Toldo C, Garattini L. Healthcare costs of multiple myeloma: an Italian study. Eur J Cancer Care (Engl). 2011;20:330–6. doi: 10.1111/j.1365-2354.2009.01153.x
  • Gaultney JG, Franken MG, Tan SS, Redekop WK, Huijgens PC, Sonneveld P, et al. Real-world healthcare costs of relapsed/refractory multiple myeloma during the era of novel cancer agents. J Clin Pharm Ther. 2013;38:41–7. doi: 10.1111/jcpt.12020
  • Teitelbaum A, Ba-Mancini A, Huang H, Henk HJ. Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data. Oncologist. 2013;18:37–45. doi: 10.1634/theoncologist.2012-0113
  • Franken MG, Gaultney JG, Blommestein HM, Huijgens PC, Sonneveld P, Redekop WK, et al. Policymaker, please consider your needs carefully: does outcomes research in relapsed or refractory multiple myeloma reduce policymaker uncertainty regarding value for money of bortezomib? Value Health. 2014;17:245–3. doi: 10.1016/j.jval.2013.12.009

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.